An early-stage study was launched by RadioMedix and Areva Med to evaluate their treatment, AlphaMedix, for safety, biodistribution and preliminary effectiveness in adult patients with somatostatin receptor-positive neuroendocrine tumors.
RadioMedix, Areva to launch early-stage trial of neuroendocrine tumor drug
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.